Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High- and Very High-risk Prostate Cancer After Radical Treatment Using Locoregional Teleradiotherapy and Hormone Therapy

NCT06449781 is registered in ClinicalTrials.gov with Maria Sklodowska-Curie National Research Institute of Oncology as lead sponsor.

NCT NCT06449781
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06449781 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High- and Very High-risk Prostate Cancer After Radical Treatment Using Locoregional Teleradiotherapy and Hormone Therapy
Lead sponsor
Maria Sklodowska-Curie National Research Institute of Oncology
Phase
Phase 2
Overall status
Recruiting
Start date
January 9, 2025
Completion date
November 30, 2030
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer